Nargenicin
CAY-25456-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
70695-02-2
Formulation
A solid
Purity
≥98%
MW
515,59532
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A macrolide antibiotic that is selective for S. aureus, MRSA, and M. luteus (MICs = 0.6, 0.3, and 2.5 μg/ml, respectively) over a panel of 11 Gram-positive and Gram-negative bacteria (MICs = >80 μg/ml); inhibits S. aureus DnaE in the presence of DNase I-activated DNA and E. coli DnaE at 0.00001-0.1 and 0.01-100 μg/mL, respectively; inhibits LPS-induced cytokine expression and nitric oxide production in murine BV-2 cells at 1 μM; reduces HL-60 cell proliferation increases cell differentiation when used in combination with 1,25-dihydroxyvitamin D3 or all-trans retinoic acid at 200 μM; reduces the number of CFUs in infected kidneys by 100,000-fold in a murine model of S. aureus infection at 50 mg/kg, p.o
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
